Institutional accumulation regime. Strong business quality combined with supportive market trend. Valuations remain demanding and supported by current metrics.
SENTINEL REVIEW
Shilpa Medicare Limited (SHILPAMED)•Updated today
🛡️ Sound Structural Profile: In FY2026, Shilpa Medicare Limited exhibits a high-quality earnings trajectory, with 210.8% YoY growth in reported net profit and a robust CFO/PAT ratio of 1.41 indicating strong cash-backed profitability. Historical monitoring thresholds around inventory and capex efficiency are currently easing as revenue momentum improves and cash generation strengthens. Balance sheet integrity remains firm, with D/E at 0.25 and operating cash flows of ₹342.2 Cr providing substantial financial capacity despite 12.2% debt growth. Temporary working-capital friction—reflected in receivable days rising to 118.9 and a 43.8% capex-to-revenue ratio—remains contained, keeping Shilpa Medicare Limited within Flagium’s stable surveillance range.
- ✓Risk score improved (QoQ change: -5 pts)
- ✓Profitability margins pressure eased
- ✗Growth expectations are demanding
- ✓Market structure is strong
- ✗A/D flow regime is Neutral (-0.12σ)
- ✗Share price is down -10.0% this quarter (from ₹1,047.2 on 30 Sept to ₹942.35)
- 🟢No severe forensic red flags active for SHILPAMED
- 🟠Track earnings quality and working capital trends in next filing
- 🟢Maintain routine quarterly surveillance; no governance escalation required
- 15.0 ptsBaseline Risk Floor
Divergence Radar
Structural Matrix
Risk vs Price TimelineVisualizing the historical relationship between the structural risk score and stock price movement over time.
| Duration | Perf. | Sector Avg | Divergence |
|---|---|---|---|
| 1 Week | -1.39% | +3.76% | -5.14% |
| 1 Month | -12.03% | -4.3% | -7.73% |
| 6 Months | +115.64% | +4.95% | +110.69% |
| 1 Year | +155.59% | +12.15% | +143.43% |
| 2 Year | +122.86% | +41.83% | +81.03% |
| 3 Year | +429.32% | +123.18% | +306.14% |
Business Analysis Methodology
Business analysis focuses on structural risk inside the company. Flagium monitors earnings quality, balance sheet strength, liquidity, governance, competitive position, and growth sustainability to identify areas where risk may be increasing or decreasing before it becomes obvious in reported results.
Financial profile remains stable for now. This indicates that forensic pressure is currently receding. Risk levels are improving.
Risk Score Composition
Investment Risk Thesis
Current risk score has risen from 7 → 15 over 12 quarters.
- Operating cash flow sustainability
- Working capital discipline
Risk Drivers (Active Warnings)
No active warnings detected.
Primary Driver & Insights
Forensic risk profile is stable. No severe operating or financial anomalies are currently pressure-testing business resilience.
Active Risk Objects (6)Free Preview (2 of 6)
SHILPAMED: Raw material costs consumed an additional 3.9% of revenue YoY.
Operating efficiency is stabilizing. The rate of margin deterioration has slowed.
Inventory growth (36.2%) significantly outpaced revenue growth (6.6%).
Inventory overhang is clearing. Stock levels are normalizing as sales momentum returns.
Unlock All 6 Forensic Signals (4 Additional Warnings Gated)
Free accounts preview the top 2 highest-impact warning signals. Upgrade to Flagium Pro to inspect all 6 active forensic detectors, multi-quarter duration streaks, and financial stress metrics for Shilpa Medicare Limited.
Statutory Note: Forensic signals are algorithmic quantitative observations derived from publicly filed XBRL disclosures and do not constitute allegations of legal misconduct or investment recommendations.
Unlock Interactive Signal Evidence Dossier
Access complete multi-quarter financial evidence, 5-KPI snapshot strips, diagnostic hypotheses, and 1-page forensic PDF dossiers for Shilpa Medicare Limited.
Structural Risk Attribution
Deterministic quarter-on-quarter causal decomposition grounded in statutory exchange filings.
Structural History · Last 12 QuartersHistorical Trajectory (12Q)
Risk improved moderately (-5.0 pts), driven by overall risk reduction across core indicators.
12-Quarter Structural Regimes & Landmark Inflections12Q Structural Regimes & Inflections
Risk deteriorated materially (+25.0 pts), driven by new Inventory Stress (+14.4 pts) and new Capex Efficiency Stress (+7.7 pts).
Business Resilience & Benchmark Context
Overall: STRONGPEER COMPARISON MATRIX
Ranked surveillance & credit risk comparison against sector peers
Stable
Stable
Watch
Watch
Watch
Watch
* Peer comparison is based on risk signals, not valuation or returns.
Unlock 5-Year Forensic Divergence Cockpit
Access multi-year visual divergence charts (EBITDA vs CFO Cash Gap, Receivables Decoupling Spread, and Debt vs FCF Burn) for Shilpa Medicare Limited.
FINANCIAL STATEMENTS
Working Capital & Forensic Monitor
Operating Cycle Disclosures·10 Fiscal Years
Working Capital Schedule (INR Cr)
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
Trade Receivables(₹ Cr) | 519 | 441 | 392 | 324 | — | — | — | — | — | — |
Inventories(₹ Cr) | 367 | 348 | 345 | 320 | — | — | — | — | — | — |
Trade Payables(₹ Cr) | 142 | 95 | 175 | 144 | — | — | — | — | — | — |
Net Working Capital(₹ Cr) | 743 | 693 | 562 | 500 | — | — | — | — | — | — |
Working Capital / Sales(%) | 48.0% | 52.9% | 48.5% | 46.8% | — | — | — | — | — | — |
Cash Conversion & Operating Cycle (Days)
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
Cash Conversion Cycle (CCC)(days) | 174d | 193d | 177d | 171d | — | — | — | — | — | — |
Debtor Days (DSO)(days) | 122d | 123d | 123d | 111d | — | — | — | — | — | — |
Inventory Days (DIO)(days) | 86d | 97d | 109d | 109d | — | — | — | — | — | — |
Creditor Days (DPO)(days) | 34d | 27d | 55d | 49d | — | — | — | — | — | — |
Forensic Accounting Monitor & Divergences
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
Receivable Growth vs Sales (Δ)(%) | -0.6% | -0.5% | +12.2% | — | — | — | — | — | — | — |
Inventory Growth vs Sales (Δ)(%) | -12.8% | -12.0% | -0.8% | — | — | — | — | — | — | — |
Asset Growth vs Sales (Δ)(%) | -6.3% | -5.9% | -2.1% | — | — | — | +0.6% | +30.3% | +0.2% | — |
Earnings-to-Cash Divergence (PAT - CFO)(₹ Cr) | -99 | -54 | -103 | -259 | -44 | — | 58 | 67 | -30 | 4 |
Accrual Ratio (Accruals / Avg Assets)(%) | -2.8% | -1.7% | -3.5% | -8.9% | — | — | 3.9% | 5.3% | -3.0% | 0.4% |
Operating Cash Realisation (CFO / EBITDA)(%) | 128.6% | 87.1% | 255.4% | — | 108.2% | — | 29.0% | 22.4% | 84.3% | 53.5% |
Capitalisation Intensity (CWIP / Assets)(%) | — | — | — | — | — | — | — | — | — | — |
Industry Intelligence
Pharmaceutical Sector KPIs| Operating Driver | Quarter | Current Value | Change (QoQ) | Change (YoY) | Industry Median |
|---|---|---|---|---|---|
| Q2 FY2027 | 64.3% | -490 bps ↓ Profitability contraction | -140 bps ↓ Profitability contraction | 64.0% |
Understanding Pharmaceutical KPIs
Concall & Management Takeaways
Q1 FY27Management focused on the company's transformation, operational leverage, and robust growth prospects, with confident and detailed commentary across divisions and forthcoming answers on strategy and outlook.
Transformation & Operational Leverage
Management emphasized the shift from a debt-heavy API business to a diversified, innovation-driven company, highlighting that reinvestment is largely behind and harvesting is ahead, with operational leverage set to drive incremental revenue and margins.
“The reinvesting is largely behind us. The harvesting is ahead of us.”
CDMO & Pipeline Monetization
CDMO remains a core growth driver, with over 25 NCE programs in various stages and only one commercial product currently; management expects significant ramp-up as more programs mature, supported by selective investments and unique partnership strategies.
“We have more than 25 such NCE programs in various stages of development. I think as and when these molecules advance, you will see the growth.”
Biologics Division Expansion
Biologics is positioned for higher growth due to a small base and industry trends, with multiple biosimilars and NBE programs advancing, and a mixed strategy of CDMO, biosimilars, and strategic partnerships for long-term value creation.
“Our first European partnering of Nivolumab with Orion Corporation gives us further assurance on commercialization of our biosimilar pipeline globally.”
Formulation Division & Complex Products
The Formulation division is seeing robust growth, driven by complex FDA portfolio launches and strong order visibility, with global expansion plans for Nor-UDCA and other specialty products.
“Overall, given existing and new pipeline launches, there is a strong likelihood of robust growth possibility in Formulation.”
- •Regulatory pathway challenges“Whilst we are working towards being very robust and compliant with our practices, once in a while, the way regulatory authorities look at us could be a bit different. And if some of those unexpected challenges come up, that might slow down the growth trajectory that we have.”
- •Global political situation impacting raw material prices“That also has to do with the recent political situation globally -- raw material prices have gone up, which ends up impacting margins, at least for the time being.”
- •U.S. tariff threats on pharmaceutical exports“I think the entire industry in India is still monitoring how the Trump administration will behave on that, and what the terms and conditions will be. I think once we have more clarity on that, it will be the right time to move on the next steps.”
Business quality remains strong.
Current forensic pressure is elevated and improving.
Key risks remain concentrated in growth sustainability and operating leverage.
The structural architecture is currently robust. Capital resilience buffers in no active risk remain well-maintained against forensic benchmarks. Systematic scans of core structural metrics confirm the absence of material structural stress. Initial structural recovery is visible; monitor for a sustained return to resilience.
Market Expectation Engine
Investor Translation • What the market price is expecting
Expectation EngineAt the current price of ₹942, the market expects this company to grow its revenue by 61.0% every year for the next 5 years. If you think the company will grow faster than 61.0%, current market prices reflect a discount relative to that growth assumption.
Sentinel Takeaway:The market expects future growth significantly above the company's historical delivery. Current market expectations appear demanding relative to the business's track record, resulting in higher expectation risk.
Using the Implied Revenue Model, the market is pricing SHILPAMED for 61.0% implied revenue growth versus 13.2% observed 3Y revenue CAGR. Current expectations appear demanding, and trailing fundamentals provide moderate support.
Business Delivery Capacity
Performance quality vs historical benchmarksHistorical business performance currently provides moderate support for the market's implied growth assumptions. Improvement in revenue growth and operating efficiency would strengthen expectation support.
WHY IS EXPECTATION RISK ELEVATED?
Valuation Context
WHAT MUST HAPPEN FOR CURRENT PRICE TO BE CORRECT?
| Assumption Metric | Required (To justify current price) | Historical Delivery (Average) | Fulfillment Assessment |
|---|---|---|---|
| Revenue Growth (CAGR) | 61.0% | 13.2% | Aggressive |
| Operating Margin (EBIT) | 18.7% | 11.1% | Aggressive |
| Free Cash Flow Conversion | -8.2% | -59.0% | Aggressive |
*Required metrics indicate the operating efficiency and revenue expansion parameters that must be sustained long-term to justify the current stock price.
The current valuation assumes business performance well above the company's historical record. Historical operating performance currently provides limited evidence that these expectations are sustainable. Continued stronger profitability and stronger cash generation would be required to justify current pricing.
Market Structure Methodology
Flagium separates Business Risk from Market Structure. Business analysis explains what is happening inside the company. Market Structure measures how investors are behaving through price trends, momentum, participation, and institutional activity. Divergences between the two often reveal important transitions before they become obvious.
The stock remains in a confirmed Stage 2 advancing phase. Institutional participation has also improved, reinforcing the constructive trend as momentum is accelerating. Current price action continues to support the prevailing advance.
What Is Driving Market Structure?
Market structure shows partial alignment with the underlying fundamental risk profile.
Market Cycle Stage Analysis
Stan Weinstein 4-Stage CycleMomentum & A/D Flow
Methodology & Regulatory Disclaimer
Flagium AI is an automated financial data analytics and research platform providing quantitative risk, forensic, and valuation analytics for informational and educational purposes only. Flagium AI is not registered with SEBI as a Research Analyst or Investment Adviser under SEBI regulations. These analytics do not constitute financial planning, investment advice, or recommendations to buy, sell, or hold any security.
Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered Investment Adviser before acting on any data presented.
📬 Flagium Risk Brief — Track forensic risks on SHILPAMED & 3 market anomalies weekly
See a sample issue →